Skip to Content

Notice

Manufacturer of Controlled Substances; Notice of Application

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 26, 2006, Sigma Aldrich Research BioChemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II:

DrugSchedule
Cathinone (1235)I
Methcathinone (1237)I
Aminorex (1585)I
Alpha-ethyltryptamine (7249)I
Start Printed Page 41839
Lysergic acid diethylamide (7315)I
Tetrahydrocannabinols (7370)I
4-Bromo-2, 5-dimethoxy-amphetamine (7391)I
4-Bromo-2, 5-dimethoxyphenethylamine (7392)I
2, 5-Dimethoxyamphetamine (7396)I
3,4-Methylenedioxyamphetamine (7400)I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)I
3,4-Methylenedioxy-N-ethylamphetamine (7404)I
3,4-Methylenedioxymethamphetamine (MDMA) (7405)I
1-[1-2-Thienyl) cyclohexyl]phetamine (TCP) (7470)I
1-Benzylpiperazine (BZP) (7493)I
Heroin (9200)I
Normorphine (9313)I
Amphetamine (1100)II
Methamphetamine (1105)II
Nabilone (7379)II
1-Phenylcyclohexylamine (7460)II
Phencyclidine (7471)II
Cocaine (9041)II
Codeine (9050)II
Diprenorphine (9058)II
Ecgonine (9180)II
Levomethorphan (9210)II
Levorphanol (9220)II
Meperidine (9230)II
Metazocine (9240)II
Methadone (9250)II
Morphine (9300)II
Thebaine (9333)II
Levo-alphacetylmethadol (9648)II
Carfentanil (9743)II
Fentanyl (9801)II

The company plans to manufacture reference standards.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 22, 2006.

Start Signature

Dated: July 10, 2006.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

End Signature End Preamble

[FR Doc. E6-11691 Filed 7-21-06; 8:45 am]

BILLING CODE 4410-09-P